Financial Daily from THE HINDU group of publications
Wednesday, Nov 09, 2005
Financial Daily from THE HINDU group of publications Wednesday, Nov 09, 2005 |
|
|
|
|
|
|
|
Corporate
-
Announcements Marketing - IPR RPG Life Sciences gets US patent for Risperidone Our Bureau
Mumbai , Nov. 8 RPG Life Sciences Ltd has got a US patent for its novel process of producing Risperidone, a pharmaceutical ingredient used in anti-psychotic medicines. RPG Life Sciences already has similar patents for Risperidone in the UK, Germany, France, Switzerland and other European markets, the company told the BSE. Risperidone is an atypical antipsychotic medication used to treat symptoms of schizophrenia. The medication decreases the abnormal excitement in the brain. The global market for the formulations of Risperidone is estimated to be over $2 billion. The company already sells Risperidone in Spain, India and other developing countries. It expects to enter other regulated markets when the patent on the product expires. The product patent expires in Europe in early-2007 and in the US in late 2007 or early 2008, a company official said. It already supplies the ingredient to other Indian companies. Formerly Searle India, RPG Life Sciences operates in the domestic and international markets with a presence in the therapeutic areas including cardiovascular, central nervous system, anti-diabetic, anti-cancer, immuno-suppressants, anti-infective and anti-inflammatory segments.
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|
